Title: ETL Automation Lead (Clinical Pharma must) || Location: Remote

0 views
Skip to first unread message

SASI KUMAR DOVALA

<sasi.kumar@intellyk.com>
unread,
May 11, 2026, 12:01:35 PM (14 hours ago) May 11
to SASI KUMAR DOVALA

Title: ETL Automation Lead (Clinical Pharma must)

Location: San Francisco, CA

Mode: 100% Remote

Shift: General



We need a proactive ETL QA Lead to drive the E2E test strategy and automation roadmap for a large-scale Palantir Foundry project. You will lead an onshore-offshore model, managing demanding stakeholders and ensuring the integrity of complex data pipelines and custom interfaces.

 

Key Responsibilities

  • E2E Strategy: Design and own the testing lifecycle for data ingestion, complex ETL rules, and Foundry-based UI.
  • Automation: Lead the automation strategy across API, UI, and ETL layers; conduct technical demos for clients.
  • Stakeholder Management: Act as the primary point of contact for clients, managing expectations and presenting quality metrics.
  • Global Leadership: Coordinate with offshore teams in India and manage delivery across multiple time zones.
  • Technical Oversight: Validate complex data transformations and ensure seamless integration between the backend and front-end UI.

 

Required Skills

  • Platform: Strong experience with Palantir Foundry (or major cloud data platforms like AWS/Azure etc.).
  • Testing Breadth: Deep expertise in ETL, API, and UI automation.
  • Operations: Proven track record in onshore-offshore coordination and proactive risk management.
  • Communication: Excellent presentation skills and the ability to handle high-pressure stakeholder environments.
  • Emerging Tech: Familiarity with testing AI/Chatbot components is a plus.





Regards,

Sasikumar

cid:image001.jpg@01DC0160.520B4230


 Address: 15 Corporate Pl S, Suite #450, Piscataway Township, NJ 08854

 Email: sasi....@intellyk.com | Website: www.intellyk.com

 cid:image002.png@01DC0160.520B4230

 

DISCLAIMER: THIS IS NOT UNSOLICITED MAIL. UNDER BILL 1618 TITLE III PASSED BY THE 105TH USA CONGRESS THIS EMAIL CANNOT BE CONSIDERED AS SPAM AS LONG AS WE INCLUDE OUR CONTACT INFORMATION AND AN OPTION TO BE REMOVED FROM OUR EMAILING LIST. IF YOU HAVE RECEIVED THIS MESSAGE IN ERROR OR, ARE NOT INTERESTED IN RECEIVING OUR EMAILS, PLEASE ACCEPT OUR APOLOGIES. PLEASE REPLY WITH REMOVE IN THE SUBJECT LINE. ALL REMOVAL REQUESTS WILL BE HONORED. WE SINCERELY APOLOGIZE FOR ANY INCONVENIENCE CAUSED

 


 



Reply all
Reply to author
Forward
0 new messages